Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2025-12-25 @ 11:32 PM
Study NCT ID:
NCT04311593
Status:
UNKNOWN
Last Update Posted:
2020-03-17
First Post:
2020-03-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016553', 'term': 'Purpura, Thrombocytopenic, Idiopathic'}], 'ancestors': [{'id': 'D011696', 'term': 'Purpura, Thrombocytopenic'}, {'id': 'D011693', 'term': 'Purpura'}, {'id': 'D001778', 'term': 'Blood Coagulation Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D057049', 'term': 'Thrombotic Microangiopathies'}, {'id': 'D013921', 'term': 'Thrombocytopenia'}, {'id': 'D001791', 'term': 'Blood Platelet Disorders'}, {'id': 'D000095542', 'term': 'Cytopenia'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D006470', 'term': 'Hemorrhage'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D018791', 'term': 'CD4 Lymphocyte Count'}], 'ancestors': [{'id': 'D018655', 'term': 'Lymphocyte Count'}, {'id': 'D007958', 'term': 'Leukocyte Count'}, {'id': 'D001772', 'term': 'Blood Cell Count'}, {'id': 'D002452', 'term': 'Cell Count'}, {'id': 'D003584', 'term': 'Cytological Techniques'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D006403', 'term': 'Hematologic Tests'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D002468', 'term': 'Cell Physiological Phenomena'}, {'id': 'D001790', 'term': 'Blood Physiological Phenomena'}, {'id': 'D002943', 'term': 'Circulatory and Respiratory Physiological Phenomena'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 68}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2020-05', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2021-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-03-14', 'studyFirstSubmitDate': '2020-03-14', 'studyFirstSubmitQcDate': '2020-03-14', 'lastUpdatePostDateStruct': {'date': '2020-03-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-03-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-05', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'measuring level of research CD markers in immue cells', 'timeFrame': 'one year', 'description': 'in acute ITP patients : at time of diagnosis and after treatment and return of platelets count to normal count.\n\nin chronic ITP patients : measuring of research CD markers once.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Immune Thrombocytopenia']}, 'referencesModule': {'references': [{'pmid': '19846889', 'type': 'BACKGROUND', 'citation': 'Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21.'}, {'pmid': '21251458', 'type': 'BACKGROUND', 'citation': 'Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus. 2011 Jul;9(3):262-73. doi: 10.2450/2010.0080-10. Epub 2010 Nov 26. No abstract available.'}, {'pmid': '19414977', 'type': 'BACKGROUND', 'citation': 'Namdev R, Dutta SR, Singh H. Acute immune thrombocytopenic purpura triggered by insect bite. J Indian Soc Pedod Prev Dent. 2009 Jan-Mar;27(1):58-61. doi: 10.4103/0970-4388.50821.'}]}, 'descriptionModule': {'briefSummary': 'In this study, we will focus on the independent prognostic relevance of the expressions of CD38, CD4, CD56, CD11b and CD19 markers in immune cells with platelet changes in patients with newly diagnosed and chronic ITP.', 'detailedDescription': "Immune thrombocytopenia (ITP), previously called idiopathic thrombocytopenia purpura, is an autoimmune disorder characterized by a severe reduction in peripheral blood platelet count. In healthy individuals, normal platelet count ranges from 150-450 × 109/L, while in thrombocytopenia counts fall to less than 100 × 109/L ( Provan et al., 2010).\n\nBased on duration, ITP is differentiated into three phases. Newly diagnosed ITP occurs within 3 months of diagnosis, persistent ITP is present 3-12 months after diagnosis, and chronic ITP lasts \\>12 months since diagnosis (Roberto, 2011).\n\nAutoantibodies against platelet glycoproteins (GPs), including GPIIb/IIIa and GPIb/IX, have been considered to play a crucial role in ITP (Nomura, 2016) . In addition to platelet destruction, impaired maturation of megakaryocytes can be associated with reduced platelet production in ITP (Muna et al., 2015).\n\nFurthermore, considerable attention has been recently paid to the dysregulation of a new B-cell subset known as regulatory B cells (Breg) in ITP (Li et al., 2012). This B-cell subset is characterized by CD19+CD38+ expression, promoting peripheral tolerance and reducing the function of autoreactive T-helper (Th) CD4+ cells via production of interleukin 10 (IL-10) (Flores-Borja et al., 2013). So they are an interesting cell population in diseases characterized by an unbalance in the immune system, such as autoimmune diseases, chronic infections, cancer and graft rejection.( Horikawa et al., 2013).\n\nIn ITP, as a result of the defective function of Breg and also Treg (regulatory T) cells, platelet autoreactive Th CD4+ cells undergo clonal expansion (McKenzie et al., 2013). so the presence of activated platelet-specific autoreactive T cells that respond to autologous platelet antigens participating in autoantibody production in ITP via interaction with autoreactive B cells (Solanilla et al., 2005).\n\nSince the early 1980s, many studies have documented decreased natural killer (NK) cell numbers and impairment of NK cell function in the peripheral blood of patients with autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, and type I diabetes (hussein et al., 2017). Furthermore, in many studies, a correlation has been found between NK cell number and activity with disease progression or remission in multiple sclerosis (MS) and systemic lupus erythematosus (SLE). (Riccieri et al., 2000).\n\nNk cells are identified by the expression of CD16 and CD56 surface markers, account for 5-15% of PB cells in healthy individuals .NK cells have a crucial role in the initial defense against infections in innate immunity and are particularly important in responding to viral infections (French and Yokoyama., 2004).\n\nThis finding suggests that CD16+CD56+ NK cells may play a role in the pathogenesis and prognosis of autoimmune diseases.\n\nCD11b+ monocytes can regulate adaptive immunity by adjustment of different T-cell subsets (Kusmartsev et al., 2000). Recently showed that monocytes derived from the whole blood of chronic ITP patients promoted the development of Th CD4+ subset (Zhong et al., 2012).\n\nAlthough the majority of these abnormalities can appear as the increased or decreased expressions of some CD markers in the involved cells, there have been few studies on the prognostic value of CD markers' expressions in immune cells for ITP."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '60 Years', 'minimumAge': '2 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Assiut university hospital - clinical hematology unit.', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Patients with thrombocytopenia were identified by their medical records. According to guidelines for the investigation and management of ITP, its diagnosis in thrombocytopenic patients was based on the following criteria: the presence of thrombocytopenia (platelet counts \\<100 9 103/lL), patient's history, physical examination, normal concentration of hemoglobin and white blood cells (WBC), PB smear examination, normal or increased number of megakaryocytes with normal myeloid and erythroid progenitors in bone marrow (BM) smears. The absence of other diseases causing thrombocytopenia, including HIV and hepatitis C infection, SLE, aplastic anemia, megaloblastic anemia, and lymphoproliferative disorders was confirmed by BM aspiration assays. In chronic ITP : ITP patients lasting for more than 12 months\n\nExclusion Criteria:\n\n* The prescence of other diseases causing thrombocytopenia, including HIV and hepatitis C infection, SLE, aplastic anemia, megaloblastic anemia and lymphoproliferative disorders was confirmed by BM aspiration assays"}, 'identificationModule': {'nctId': 'NCT04311593', 'briefTitle': 'Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura', 'organization': {'class': 'OTHER', 'fullName': 'Assiut University'}, 'officialTitle': 'Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura', 'orgStudyIdInfo': {'id': 'CD markers in ITP'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'group 1', 'description': 'control group with normal platelet count', 'interventionNames': ['Diagnostic Test: CD4, CD19, CD38, CD56 and CD11b']}, {'label': 'group 2', 'description': 'patients with acute ITP', 'interventionNames': ['Diagnostic Test: CD4, CD19, CD38, CD56 and CD11b']}, {'label': 'group 3', 'description': 'patients with chronic ITP', 'interventionNames': ['Diagnostic Test: CD4, CD19, CD38, CD56 and CD11b']}], 'interventions': [{'name': 'CD4, CD19, CD38, CD56 and CD11b', 'type': 'DIAGNOSTIC_TEST', 'description': 'measuring CD markers by flowcytometry', 'armGroupLabels': ['group 1', 'group 2', 'group 3']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'esraa ahmed mahmoud, resident doctor', 'role': 'CONTACT', 'email': 'dresraaahmed@gmail.com', 'phone': '+201011783088'}, {'name': 'rania mohammed mahmoud, assistant prof.', 'role': 'CONTACT', 'phone': '+201000019198'}], 'overallOfficials': [{'name': 'Essam ELdeen abdmohsen mohammed, Professor', 'role': 'STUDY_DIRECTOR', 'affiliation': '+201001971906'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Assiut University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'resident doctor', 'investigatorFullName': 'Esraa Ahmed Mahmoud', 'investigatorAffiliation': 'Assiut University'}}}}